William Sievert

14.2k total citations · 2 hit papers
154 papers, 6.5k citations indexed

About

William Sievert is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, William Sievert has authored 154 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Hepatology, 110 papers in Epidemiology and 30 papers in Surgery. Recurrent topics in William Sievert's work include Hepatitis C virus research (85 papers), Liver Disease Diagnosis and Treatment (79 papers) and Hepatitis B Virus Studies (69 papers). William Sievert is often cited by papers focused on Hepatitis C virus research (85 papers), Liver Disease Diagnosis and Treatment (79 papers) and Hepatitis B Virus Studies (69 papers). William Sievert collaborates with scholars based in Australia, United States and United Kingdom. William Sievert's co-authors include Patrick Marcellin, Seng Gee Lim, Myron J. Tong, Edward Gane, Marı́a Buti, John F. Flaherty, Carol Brosgart, John Fry, Ira M. Jacobson and Lennox J. Jeffers and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

William Sievert

145 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

2012 1.3k citations Patrick Marcellin, Edward Gane et al. profile →
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B

2003 1.0k citations Patrick Marcellin, Seng Gee Lim et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Sievert Australia	35	4.8k	4.6k	771	680	574	154	6.5k
Antonina Smedile Italy	41	6.7k 1.4×	6.6k 1.4×	584 0.8×	592 0.9×	502 0.9×	199	8.1k
Vincent Mallet France	35	3.7k 0.8×	3.7k 0.8×	720 0.9×	568 0.8×	478 0.8×	128	5.8k
Vincent Thibault France	42	5.0k 1.1×	5.4k 1.2×	382 0.5×	1.0k 1.5×	250 0.4×	159	7.0k
Tetsuya Hosaka Japan	47	7.3k 1.5×	7.3k 1.6×	543 0.7×	667 1.0×	585 1.0×	324	9.0k
John M. Vierling United States	44	5.9k 1.2×	7.1k 1.5×	1.9k 2.5×	891 1.3×	479 0.8×	213	8.7k
G. Realdi Italy	44	4.6k 1.0×	4.3k 0.9×	1.4k 1.8×	450 0.7×	619 1.1×	187	7.3k
Lennox J. Jeffers United States	41	6.4k 1.4×	6.4k 1.4×	1.1k 1.4×	738 1.1×	327 0.6×	136	8.3k
Theo Heller United States	46	4.0k 0.8×	3.3k 0.7×	872 1.1×	605 0.9×	1.2k 2.1×	235	7.3k
Peter Buggisch Germany	29	3.3k 0.7×	3.4k 0.7×	278 0.4×	586 0.9×	413 0.7×	192	4.9k
Chuan–Mo Lee Taiwan	40	4.3k 0.9×	4.3k 0.9×	780 1.0×	505 0.7×	481 0.8×	122	5.9k

Countries citing papers authored by William Sievert

Since Specialization

Citations

This map shows the geographic impact of William Sievert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Sievert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Sievert more than expected).

Fields of papers citing papers by William Sievert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Sievert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Sievert. The network helps show where William Sievert may publish in the future.

Co-authorship network of co-authors of William Sievert

This figure shows the co-authorship network connecting the top 25 collaborators of William Sievert. A scholar is included among the top collaborators of William Sievert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Sievert. William Sievert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lim, Rebecca, Alexander Hodge, Gregory Moore, et al.. (2024). Human Amniotic Epithelial Cell Transplantation is Safe and Well Tolerated in Patients with Compensated Cirrhosis: A First-in-Human Trial. Stem Cells Translational Medicine. 13(6). 522–531. 6 indexed citations

Clark, Paul J., Patricia C. Valery, Simone I. Strasser, et al.. (2023). Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care. Journal of Gastroenterology and Hepatology. 39(3). 568–575. 2 indexed citations

Feehan, Jack, Alexandra Mack, Caroline J. Tuck, et al.. (2023). Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease—A Single Blinded Crossover Trial. Nutrients. 15(23). 4870–4870. 14 indexed citations

Gane, Edward, Won Kim, Tien Huey Lim, et al.. (2023). First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection. Journal of Hepatology. 79(5). 1139–1149. 25 indexed citations

Roberts, Stuart K., Ammar Majeed, John Lubel, et al.. (2022). Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease. Liver International. 43(1). 90–99. 22 indexed citations

Schwab, Renate, Dandan Zhu, Gina D. Kusuma, et al.. (2021). Amnion Epithelial Cells — a Therapeutic Source. Current Stem Cell Reports. 7(1). 13–29. 3 indexed citations

Con, Danny, et al.. (2021). Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools. Hepatology International. 15(3). 812–820. 5 indexed citations

Hodge, Alexander, et al.. (2020). Human Amnion Epithelial Cells Produce Soluble Factors that Enhance Liver Repair by Reducing Fibrosis While Maintaining Regeneration in a Model of Chronic Liver Injury. Cell Transplantation. 29. 2790874670–2790874670. 7 indexed citations

Balic, Jesse J., Mohamed I. Saad, Louise McLeod, et al.. (2020). Constitutive STAT3 Serine Phosphorylation Promotes Helicobacter-Mediated Gastric Disease. American Journal Of Pathology. 190(6). 1256–1270. 20 indexed citations

10.

Gillespie, Elizabeth, et al.. (2016). USING ADENOSINETRIPHOSPHATE BIOLUMINESCENCE TO VALIDATE DECONTAMINATION FOR DUODENOSCOPES.. PubMed. 24(4). 26–8. 4 indexed citations

11.

Holmes, Julie, M Congiu, Sally Bell, et al.. (2015). The relationships between IFNL4 genotype, intrahepatic interferon‐stimulated gene expression and interferon treatment response differs in HCV‐1 compared with HCV‐3. Alimentary Pharmacology & Therapeutics. 42(3). 296–306. 10 indexed citations

12.

Hodge, Alexander, Dinushka Lourensz, Vijesh Vaghjiani, et al.. (2014). Soluble factors derived from human amniotic epithelial cells suppress collagen production in human hepatic stellate cells. Cytotherapy. 16(8). 1132–1144. 46 indexed citations

13.

Agarwal, Kosh, Yves Horsmans, William Sievert, et al.. (2013). 798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY. Journal of Hepatology. 58. S326–S326. 6 indexed citations

14.

Lim, Lucy, Scott J. Patterson, Jacob George, et al.. (2012). Tenofovir Rescue Therapy Achieves Long-Term Suppression of HBV Replication in Patients with Multi-Drug Resistant HBV: 4 Year Follow-Up of the TDF109 Cohort. Hepatology. 56. 3 indexed citations

15.

Sievert, William, G.J. Dore, Geoffrey W. McCaughan, et al.. (2009). SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDY. Hepatology. 50(4). 1 indexed citations

16.

Sievert, William. (2003). Antiviral therapy for chronic hepatitis C.. PubMed. 32(10). 826–32. 6 indexed citations

17.

Marcellin, Patrick, Ting‐Tsung Chang, Seng Gee Lim, et al.. (2002). 48 weeks of adefovir dipivoxil (ADV) results in improvement in fibrosis and decreased progression of fibrosis in a double-blind, randomized, placebo-controlled study for the treatment of patients with HBeAg plus chronic hepatitis B.. Hepatology. 36(4). 3 indexed citations

18.

Sievert, William. (2002). Management issues in chronic viral hepatitis: Hepatitis C. Journal of Gastroenterology and Hepatology. 17(4). 415–422. 17 indexed citations

19.

Dev, Anouk & William Sievert. (2002). A survey of Australian general practice management of hepatitis C‐infected patients from non‐English‐speaking backgrounds. Journal of Gastroenterology and Hepatology. 17(3). 295–300. 17 indexed citations

20.

Marcellin, Patrick, Ting‐Tsung Chang, Seng Gee Lim, et al.. (2001). GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results.. Hepatology. 34(4). 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact